

Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

Clinical Infectious Diseases

61, 572-580

DOI: 10.1093/cid/civ324

Citation Report

#	ARTICLE	IF	CITATIONS
1	Low Bone Mass in Behaviorally HIV-Infected Young Men on Antiretroviral Therapy: Adolescent Trials Network Study 021B. <i>Clinical Infectious Diseases</i> , 2012, 55, 461-468.	5.8	52
2	Bone loss in HIV. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 446-451.	2.3	56
3	<i>Editorial Commentary</i>: Unmasking the Bare Bones of HIV Preexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2015, 61, 581-583.	5.8	3
4	HIV epidemics among transgender populations: the importance of a trans-inclusive response. <i>Journal of the International AIDS Society</i> , 2016, 19, 21259.	3.0	1
5	Tenofovir and bone health. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 326-332.	3.8	105
6	Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1287-1294.	2.4	5
7	Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 287-294.	2.1	42
8	The preexposure prophylaxis revolution; from clinical trials to programmatic implementation. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 80-86.	3.8	84
9	The protease inhibitors and HIV-associated bone loss. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 333-342.	3.8	36
10	Key Data from the <i>17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV</i>. <i>Antiviral Therapy</i> , 2016, 21, 75-89.	1.0	5
11	Protecting bone in long-term HIV positive patients receiving antiretrovirals. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 587-599.	4.4	4
12	Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. <i>Aids</i> , 2016, 30, 1973-1983.	2.2	721
13	Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. <i>Lancet HIV</i> , 2016, 3, e521-e528.	4.7	66
14	HIV and Bone Complications: Understudied Populations and New Management Strategies. <i>Current HIV/AIDS Reports</i> , 2016, 13, 349-358.	3.1	21
15	Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How. <i>Infectious Diseases and Therapy</i> , 2016, 5, 407-416.	4.0	15
16	PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305). <i>Journal of Infectious Diseases</i> , 2017, 215, jiw525.	4.0	40
17	Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 252-257.	2.1	25
18	Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices. <i>Journal of the International AIDS Society</i> , 2016, 19, 20810.	3.0	67

#	ARTICLE	IF	CITATIONS
19	Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment. <i>Aids</i> , 2016, 30, 915-920.	2.2	12
20	Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. <i>Clinical Infectious Diseases</i> , 2016, 62, 1172-1177.	5.8	40
21	Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 265-273.	2.4	31
22	Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings. <i>Current HIV/AIDS Reports</i> , 2016, 13, 116-124.	3.1	76
23	Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin?. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv221.	0.9	11
24	Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 195-209.	4.4	22
25	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 377-383.	0.5	11
26	Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 169-175.	1.6	2
27	Bone Loss in HIV Infection. <i>Current Treatment Options in Infectious Diseases</i> , 2017, 9, 52-67.	1.9	37
28	HIV preexposure prophylaxis for adolescents and young adults. <i>Current Opinion in Pediatrics</i> , 2017, 29, 399-406.	2.0	33
29	Sexually transmissible infection control programs for men who have sex with men “what will they look like in 2020?”. <i>Sexual Health</i> , 2017, 14, 126.	0.9	4
30	Emtricitabine/tenofovir disoproxil fumarate in HIV-1 pre-exposure prophylaxis: a guide to its once-daily use in the EU. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 8-15.	0.6	0
31	Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. <i>Aids</i> , 2017, 31, 2245-2251.	2.2	47
32	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women. <i>Annals of Internal Medicine</i> , 2017, 167, 384.	3.9	29
33	Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. <i>JAMA Pediatrics</i> , 2017, 171, 1063.	6.2	178
34	An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 21-29.	2.1	235
35	Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 177-182.	2.1	25
36	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2017, 35, 377-383.	0.3	0

#	ARTICLE	IF	CITATIONS
37	Bone health in HIV and hepatitis B or C infections. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017, 9, 22-34.	2.7	32
38	Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2017, 64, 317-325.	5.8	54
39	Preexposure Prophylaxis in the United States: An Evolving HIV Prevention Opportunity. <i>Clinical Infectious Diseases</i> , 2017, 64, 150-151.	5.8	2
40	Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care. <i>Journal of General Internal Medicine</i> , 2017, 32, 192-198.	2.6	88
41	Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature. <i>Antiviral Therapy</i> , 2017, 23, 379-382.	1.0	0
42	Recent advances in pre-exposure prophylaxis for HIV. <i>BMJ: British Medical Journal</i> , 2017, 359, j5011.	2.3	101
43	Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. <i>Clinical Infectious Diseases</i> , 2018, 67, 411-419.	5.8	50
44	Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1712-1721.	5.8	48
45	HIV preexposure prophylaxis: An essential, safe and effective prevention tool for sexual health. <i>MÃ©decine Et Maladies Infectieuses</i> , 2018, 48, 318-326.	5.0	5
46	Bone density, microarchitecture, and tissue quality after 1 year of treatment with tenofovir disoproxil fumarate. <i>Aids</i> , 2018, 32, 913-920.	2.2	26
47	Potential kidney toxicity from the antiviral drug tenofovir. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 102-112.	2.0	17
48	Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. <i>Lancet, The</i> , 2018, 391, 839-849.	13.7	286
49	The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. <i>Journal of the International AIDS Society</i> , 2018, 21, e25096.	3.0	24
50	Female and younger subjects have lower adherence in PrEP trials: a meta-analysis with implications for the uptake of PrEP service to prevent HIV. <i>Sexually Transmitted Infections</i> , 2018, 94, 163-168.	1.9	36
51	Advancing HIV Biomedical Prevention Research for At-Risk Adolescents. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 535-542.	2.1	7
52	Feasibility of vitamin D supplementation interventions to mitigate HIV pre-exposure prophylaxis-related bone mineral density loss: a cross-sectional survey. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2197-2204.	1.8	3
54	Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy275.	0.9	5
55	Qualitative Insights Into Adherence to HIV Pre-Exposure Prophylaxis (PrEP) Among Australian Gay and Bisexual Men. <i>AIDS Patient Care and STDs</i> , 2018, 32, 519-528.	2.5	10

#	ARTICLE	IF	CITATIONS
56	HIV Pre-Exposure Prophylaxis Medication for Adolescents and Young Adults: A Position Paper of the Society for Adolescent Health and Medicine. <i>Journal of Adolescent Health</i> , 2018, 63, 513-516.	2.5	30
57	Daily HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine reduced <i>Streptococcus</i> and increased <i>Erysipelotrichaceae</i> in rectal microbiota. <i>Scientific Reports</i> , 2018, 8, 15212.	3.3	24
59	Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women. <i>PLoS ONE</i> , 2018, 13, e0195744.	2.5	6
60	Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention in Adolescents and Young Adults. <i>Current Pediatrics Reports</i> , 2018, 6, 114-122.	4.0	11
61	Impact of Tenofovir-Based Pre-exposure Prophylaxis on Biomarkers of Bone Formation, Bone Resorption, and Bone Mineral Metabolism in HIV-Negative Adults. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz338.	0.9	3
62	Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions. <i>Drugs</i> , 2019, 79, 1263-1276.	10.9	53
63	Antiretroviral Medications for the Prevention of HIV Infection. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 629-646.	5.1	6
64	Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. <i>Bioconjugate Chemistry</i> , 2019, 30, 2216-2227.	3.6	13
65	Pre-exposure prophylaxis for HIV infection may be effective in older candidates, but proceed with caution. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 21-23.	0.6	0
66	Primary Care Physician Attitudes and Intentions Toward the Use of HIV Pre-exposure Prophylaxis in Adolescents in One Metropolitan Region. <i>Journal of Adolescent Health</i> , 2019, 64, 581-588.	2.5	26
67	Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 788-793.	1.1	8
68	Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 746-754.	1.1	3
69	Nonoccupational Postexposure Prophylaxis and Preexposure Prophylaxis for Human Immunodeficiency Virus Prevention in Adolescents and Young Adults. <i>Advances in Pediatrics</i> , 2019, 66, 245-261.	1.4	3
70	Preexposure Prophylaxis for the Prevention of HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2214.	7.4	172
71	Preexposure Prophylaxis for the Prevention of HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2203.	7.4	219
72	Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 1339-1352.	2.4	7
73	Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24â€“week analysis (RIDAR). <i>Tj ETQq0 0.0 rgBT / Overlock 10</i>	2.4	7
74	BHIVA/BASHH guidelines on the use of HIV preâ€“exposure prophylaxis (PrEP) 2018. <i>HIV Medicine</i> , 2019, 20, s2-s80.	2.2	30

#	ARTICLE	IF	CITATIONS
75	Effect of Vitamin D Supplementation on Bone Turnover Markers During HIV Pre-Exposure Prophylaxis Using Tenofovir Disoproxil Fumarate-Emtricitabine in Men Who Have Sex with Men. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 608-614.	1.1	4
76	Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Caseâ€“Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, 214-223.	2.1	8
77	Scaling-up PrEP Delivery in Sub-Saharan Africa: What Can We Learn from the Scale-up of ART?. <i>Current HIV/AIDS Reports</i> , 2019, 16, 141-150.	3.1	51
78	Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz463.	0.9	9
79	Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis. <i>Osteoporosis International</i> , 2019, 30, 1125-1135.	3.1	23
80	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet, The</i> , 2019, 393, 143-155.	13.7	265
81	Predictors of Daily Adherence to HIV Pre-exposure Prophylaxis in Gay/Bisexual Men in the PRELUDE Demonstration Project. <i>AIDS and Behavior</i> , 2019, 23, 1287-1296.	2.7	14
82	Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 123-128.	1.1	7
83	Viewpoint: Why you should provide HIV pre-exposure prophylaxis (PrEP) at your college health center. <i>Journal of American College Health</i> , 2020, 68, 119-123.	1.5	1
84	Bone Health in Patients With Liver Diseases. <i>Journal of Clinical Densitometry</i> , 2020, 23, 212-222.	1.2	27
85	Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. <i>Clinical Infectious Diseases</i> , 2020, 70, 687-691.	5.8	22
86	Emerging evidence from a systematic review of safety of preâ€“exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?. <i>Journal of the International AIDS Society</i> , 2020, 23, e25426.	3.0	67
87	Preexposure Prophylaxis for Human Immunodeficiency Virus Infection for Men Who Have Sex with Men and Transgender Persons:. <i>Dermatologic Clinics</i> , 2020, 38, 233-238.	1.7	0
88	Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatmentâ€“Naïve Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 83, 310-318.	2.1	127
89	Acute Weight Gain After Switch to Emtricitabine/Tenofovir Alafenamide for Human Immunodeficiency Virus Pre-Exposure Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa454.	0.9	3
90	<i>In Vitro</i> Exposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression Profiles. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	8
91	Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV preâ€“exposure prophylaxis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25624.	3.0	7
92	Sexual <sc>orientationâ€“based</sc> disparities in bone health: Evidence of reduced bone mineral density and mineral content among sexual minority men but not women in multiple <sc>NHANES</sc> waves. <i>American Journal of Human Biology</i> , 2021, 33, e23534.	1.6	2

#	ARTICLE	IF	CITATIONS
93	Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE-2). <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1332-1337.	3.0	8
94	Implementing PrEP in the pharmacy. <i>Pharmacy Today</i> , 2020, 26, 39-53.	0.0	3
95	Vitamin D and Calcium Supplement Attenuate Bone Loss among HIV-Infected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial. <i>Current HIV Research</i> , 2020, 18, 52-62.	0.5	4
96	Bone Mineral Density, Body Composition, and Mineral Homeostasis Over 24-Months in Urban South African Women With HIV Exposed to Antiretroviral Therapy. <i>JBM Plus</i> , 2020, 4, e10343.	2.7	11
97	Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate?. <i>Current HIV/AIDS Reports</i> , 2020, 17, 1-5.	3.1	9
98	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. <i>Annual Review of Immunology</i> , 2020, 38, 673-703.	21.8	74
99	Evaluation of the Microbiome in Men Taking Pre-exposure Prophylaxis for HIV Prevention. <i>AIDS and Behavior</i> , 2021, 25, 2005-2013.	2.7	9
100	Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial. <i>PLoS ONE</i> , 2021, 16, e0246272.	2.5	6
101	Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2021, 10, 165-186.	4.0	13
102	Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1367-1373.	2.4	11
103	Pre-Exposure Prophylaxis (PrEP) for HIV Infection in Cisgender and Transgender Women in the U.S.: A Narrative Review of the Literature. <i>Archives of Sexual Behavior</i> , 2021, 50, 1713-1728.	1.9	19
104	Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2129-2136.	3.0	10
105	Inflammatory cytologic alterations in the oral epithelium associated with HIV pre-exposure prophylaxis: a preliminary study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2021, 131, 534-539.	0.4	2
106	Human Immunodeficiency Virus Pre-Exposure Prophylaxis: Use of Emtricitabine/Tenofovir Alafenamide. <i>Journal for Nurse Practitioners</i> , 2021, 17, 673-676.	0.8	1
107	The benefits of tenofovir discontinuation with or without bisphosphonate therapy in osteoporotic people living with HIV. <i>HIV Medicine</i> , 2021, 22, 816-823.	2.2	4
108	The combined effects of age and HIV on the anatomic distribution of cortical and cancellous bone in the femoral neck among men and women. <i>Aids</i> , 2021, Publish Ahead of Print, 2513-2522.	2.2	2
109	Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. <i>Aids</i> , 2021, 35, 2481-2487.	2.2	8
110	Case 27-2021: A 16-Year-Old Boy Seeking Human Immunodeficiency Virus Prophylaxis. <i>New England Journal of Medicine</i> , 2021, 385, 1034-1041.	27.0	0

#	ARTICLE	IF	CITATIONS
111	Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women. Expert Opinion on Drug Safety, 2017, 16, 867-871.	2.4	14
112	The Effect of Tenofovir Disoproxil Fumarate on Bone Mineral Density: A Systematic Review and Meta-Analysis. Antiviral Therapy, 2020, 25, 21-32.	1.0	26
113	Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305. Journal of Antimicrobial Chemotherapy, 2022, 77, 500-506.	3.0	2
114	HIV pre-exposure prophylaxis and sexually transmitted infections: intersection and opportunity. Nature Reviews Urology, 2022, 19, 7-15.	3.8	6
115	Acceptance of HIV Pre-Exposure Prophylaxis (PrEP) Program at STD Clinic. Archives of Infectious Diseases & Therapy, 2018, 2, .	0.0	0
116	Prevalence and risk factors for bone mineral density changes in antiretroviral therapy-naïve human immunodeficiency virus-infected adults: a Chinese cohort study. Chinese Medical Journal, 2020, 133, 2940-2946.	2.3	4
118	CROI 2016: Complications of HIV Infection and Antiretroviral Therapy. Topics in Antiviral Medicine, 2016, 24, 38-46.	0.1	2
119	How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. Journal of Virus Eradication, 2018, 4, 215-224.	0.5	34
120	CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women. BMJ Open, 2022, 12, e052880.	1.9	18
121	Navigating Human Immunodeficiency Virus and Primary Care Concerns Specific to the Transgender and Gender-Nonbinary Population. Open Forum Infectious Diseases, 2022, 9, ofac091.	0.9	0
122	Impact of Liver Cirrhosis on Bone Metabolism. Digestive Disease Interventions, 0, , .	0.2	0
123	Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305). AIDS and Behavior, 0, , .	2.7	1
125	Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults. Current Opinion in HIV and AIDS, 2022, 17, 199-204.	3.8	1
126	HIV Transmission Prevention. , 2021, , 30-50.		0
127	Preexposure Prophylaxis for the Prevention of HIV. JAMA - Journal of the American Medical Association, 2023, 330, 746.	7.4	6
128	Pre-exposure prophylaxis for prevention of HIV infection. Singapore Medical Journal, 2023, 64, 624-628.	0.6	0
129	Cytogenetic changes in oral mucosa cells from individuals submitted to oral human immunodeficiency virus pre-exposure prophylaxis use. Revista Da Associação Médica Brasileira, 2023, 69, .	0.7	0
130	Humeral Shaft Fracture Nonunion and HIV Pre-exposure Prophylaxis (PrEP): A Case Report. , 2023, 1, .		0

#	ARTICLE	IF	CITATIONS
131	Effects of Tenofovir Disoproxil Fumarate on Bone Quality beyond Bone Density”A Scoping Review of the Literature. Pharmaceuticals, 2024, 17, 146.	3.8	0
132	Acute facial neuralgia related to initiation of emtricitabine/tenofovir for HIV PrEP: a report of two cases in a PrEP demonstration trial. Sexual Health, 2024, 21, .	0.9	0